TSTara Sanft

Tara Sanft

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tara Sanft has a total of 151 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    Patient-Clinician Communication: ASCO Guideline Update

    by Timothy Gilligan, Kari Bohlke, Ash B. Alpert, Nessa Coyle, Seema Harichand-Herdt, Christopher S. Lathan, Evangelia Razis, Kimberly Rivera, Tara Sanft, Carole Seigel, et al.

    ASCO Guidelines provide recommendations with comprehensive review and analyses of the relevant literature for each recommendation, following the guideline development process as outlined in the ASCO Guidelines Methodology Manual . ASCO Guidelines follow the ASCO Conflict of Interest Policy for Clinical Practice Guidelines . Clinical Practice Guidelines and other guidance (“Guidance”) provided by ASCO is not a comprehensive or definitive guide to treatment options. It is intended for voluntary use by clinicians and should be used in conjunction with independent professional judgment. Guidance may not be applicable to all patients, interventions, diseases or stages of diseases. Guidance is based on review and analysis of relevant literature and is not intended as a statement of the standard of care. ASCO does not endorse third-party drugs, devices, services, or therapies and assumes no responsibility for any harm arising from or related to the use of this information. See complete disclaimer in Appendix 1 and Appendix 2 (online only) for more. PURPOSE: To provide guidance to oncology clinicians on using effective communication to optimize the patient-clinician relationship, patient and clinician well-being, and caregiver well-being. METHODS: ASCO convened a multidisciplinary panel of medical oncologists, hematologists, nurses, hospice and palliative medicine clinicians, and communication skills and advocacy experts to develop recommendations. Guideline development involved a systematic review of the literature and a formal consensus process. The systematic review encompassed systematic reviews and randomized controlled trials (RCTs) published from October 1, 2016, through January 16, 2025. RESULTS: The systematic review identified 73 publications (54 systematic reviews and 19 RCTs). Included studies varied with respect to setting and the interventions and outcomes evaluated. Recommendations were developed using a formal consensus process. Draft recommendations underwent two rounds of consensus voting before being finalized. RECOMMENDATIONS: Recommendations address core communication skills and tasks that apply across the continuum of cancer care, as well as specific topics such as discussion of goals of care and prognosis, treatment selection, end-of-life care, facilitating involvement of the patient's support network, and clinician training in communication skills. In addition, new topics addressed by this update include telehealth, interprofessional communication, and boundary setting. Recommendations are accompanied by suggested strategies for implementation. Full implementation of communication best practices will require that health systems provide adequate time, training, and support for clinicians. Additional information is available at https://ascopubs.org/topics/asco-guidelines/supportive-care-quality-life .


  • Sleep disturbance trajectories in cancer survivors during the transition to survivorship: a prospective examination of modifiable predictors and physical health outcomes

    by Mariel Emrich, Katherine E Gnall, Zachary E Magin, Keith M Bellizzi, Crystal L Park, Tara Sanft

    Background: Sleep disturbance is common among cancer survivors, but more research is needed to understand individual differences and predictors during the transition from primary treatment to early survivorship. Purpose: This study aimed to: (1) model sleep disturbance trajectories among cancer survivors from post-primary treatment into early survivorship, (2) examine the relationships of general (i.e., anxiety, depression, emotion dysregulation) and cancer-specific (i.e., illness beliefs, fear of cancer recurrence) factors with sleep disturbance trajectories, and (3) examine the association between sleep disturbance trajectories and changes in physical health. Methods: A total of 501 breast, colorectal, and prostate cancer survivors (24-80 years old, 69.9% female, 84.6% White) completed self-report measures at baseline (approximately 3 months post-primary cancer treatment) and 3-, 6-, 9-, and 12-month follow-ups. Latent class linear mixed modeling identified distinct trajectories of sleep disturbance. Psychosocial correlates of trajectory membership were examined using multinomial logistic regression. A linear regression tested whether sleep trajectory class was associated with changes in physical health over one year. Results: Three sleep disturbance trajectories were identified: low and slightly improving (44.3%), average and slightly improving (32.9%), and high and slightly improving (22.8%). Individually, higher emotion dysregulation, anxiety, depression, fear of cancer recurrence, and illness beliefs significantly differentiated the high sleep disturbance group from the low and average groups. In the combined model, only anxiety and depression symptoms remained significant. The high sleep disturbance group had significantly less improvement in physical health over one year compared to the low group. Conclusions: Both general and cancer-specific psychosocial factors appear to play a key role in identifying individuals at risk for persistent sleep disturbance following cancer treatment. Sleep disturbance trajectories were also associated with changes in physical health over one year, underscoring the importance of early intervention.

  • Development of an Exercise Question Prompt List for Breast Cancer Survivors

    by Oliver W.A. Wilson, Tara Sanft, Isaac J. Ergas, Jacob Schneider, Yuru Huang, Gisela Butera, Quynh C. Nguyen, Brenda L. Curtis, Richard L. Street, Jinani Jayasekera

    Background : High-quality communication about exercise during clinical visits may increase participation among breast cancer survivors. However, survivors’ exercise participation and communication preferences remain poorly understood. The aims of this study were to synthesize existing evidence on breast cancer survivors’ exercise participation and communication preferences and to refine a question prompt list (QPL) with expert input. Methods : A systematic scoping review was conducted in accordance with PRISMA-ScR guidelines. Five databases were searched for articles reporting survivors’ exercise participation and communication preferences worldwide between January 2005 and July 2025. Survivor characteristics and exercise preferences were extracted and used to draft a QPL. Weighted average percentages for preferences were calculated. Experts provided feedback through interviews, and the QPL was iteratively revised accordingly. Results : Twenty-nine studies were identified. Overall, preferences were found for exercise frequency (77.6%: ≥2 sessions/wk), intensity (63.1%: moderate intensity), and duration (62.9%: 30–60 min/session). Preferred locations included home (29.3%), community recreation facilities (32.9%), and outdoors (31.4%). Supervised exercise (53.4%) and exercising with others (57.7%) were preferred over unsupervised (35.2%) and solo (34.4%) exercise, respectively. Survivors preferred exercise counseling/advice from an exercise specialist (59.3%) and face-to-face delivery (63.7%). Experts (n = 10) viewed the QPL favorably and recommended modifications to improve comprehension, as well as additional questions on willingness to pay and travel for exercise, and interest in diet/nutrition information. Conclusions : Survivor preferences and expert input are reflected in the novel QPL. With further testing, the QPL may support the delivery of guideline-aligned exercise information. Future research should evaluate the QPL’s impact on survivors’ exercise participation and psychological antecedents of exercise (eg, self-efficacy).

  • Open Access

    Effect of a lifestyle intervention during chemotherapy for breast cancer on quality of life

    by Leah S Puklin, Fang-Yong Li, Leah M Ferrucci, Brenda Cartmel, Maura Harrigan, Courtney McGowan, Michelle Zupa, Jennifer A Ligibel, Tara Sanft, Melinda L Irwin

    Background: Chemotherapy-induced side effects can diminish physical and psychological well-being for women with breast cancer. Although nutrition and exercise improve quality of life (QoL) posttreatment, their ability to attenuate treatment-related declines in QoL during chemotherapy remains underexplored. Methods: Women diagnosed with stage I-III breast cancer initiating chemotherapy were randomized to a yearlong nutrition and exercise intervention (I; n = 87) or usual care (UC; n = 86). Patient-Reported Outcomes Measurement Information System (PROMIS)-29, PROMIS Cognitive Function, and PROMIS Global Health scales were assessed at diagnosis (baseline), postchemotherapy (PC), 1-year, and 2-years postrandomization. Results: Participants (N = 173) were on average 52.8 ± 11.1 years of age and 51% had stage I breast cancer. At diagnosis, PROMIS scores were comparable to the general US population, except for heightened anxiety. PROMIS scores worsened from diagnosis to PC for physical function (I = −5.5 (1.0); UC = −5.4 (1.0)), fatigue (I = 5.4 (1.1); UC = 6.2 (1.1)), social roles (I = −5.4 (1.0); UC = −7.1 (1.0)), cognitive function (I = −4.8 (1.0); UC = −4.3 (1.1)), global physical health (I = −10.9 (0.8); UC = −10.1 (0.8)), and global mental health (I = −11.2 (1.1); UC = −9.7 (1.2)), with anxiety improving (I = −5.1 (0.9); UC = −3.7 (0.9)). No between-arm differences were observed. By 1 year, most scores returned to baseline levels and remained stable through 2 years, except anxiety, which remained improved. Conclusion: Despite improving nutrition and exercise, the intervention did not attenuate declines in QoL compared with UC. This study fills a gap on interventions with nutrition and exercise components during chemotherapy and highlights needing more research to identify those most likely to have benefits in QoL from lifestyle interventions delivered during active treatment. Clinical Trial Registration: NCT03314688


  • Open Access

    Longitudinal Curriculum to Address Wellness and Professional Development in a Hematology/Oncology Fellowship Program

    by Thejal Srikumar, Jessica M. Stempel, Sarah B. Goldberg, Nikolai A. Podoltsev, David A. Braun, Alfred I. Lee, Tara Sanft

    Burnout is widespread in medicine, with up to 60% of oncologists and 20% of oncology fellows in the USA reporting burnout. Currently...

  • Improving lifestyle behaviors during chemotherapy for breast cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis (LEANer) Trial

    by Leah S. Puklin, Leah M. Ferrucci, Maura Harrigan, Courtney McGowan, Michelle Zupa, Brenda Cartmel, Fang‐Yong Li, Jennifer A. Ligibel, Donna Spiegelman, Mona Sharifi, et al.

    Background: Little is known about improving physical activity (PA) and diet during and after chemotherapy for breast cancer. This secondary analysis examines changes in PA and diet quality during a yearlong intervention for patients with breast cancer undergoing chemotherapy and evaluates factors associated with these changes.Methods: Newly diagnosed patients with breast cancer (N = 173) undergoing chemotherapy were randomized to a year‐long nutrition and exercise intervention (n = 87) or usual care (UC, n = 86). Mixed models compared 1‐year changes in PA and diet quality via the Healthy Eating Index (HEI)‐2015 by study arm. Among the intervention group, baseline factors associated with change in PA and diet were assessed with multivariable linear and logistic regression.Results: At 1 year, compared with UC, the intervention arm increased PA more (mean difference = 136.1 minutes/week; 95% CI, 90.2–182.0), participated in more strength training (56% vs. 15%; p < .001), and had suggestive improvements in HEI‐2015 (mean difference = 2.5; 95% CI, –0.3 to 5.3; p = .08). In the intervention arm, lower fatigue was associated with improved PA (p = .04) and higher education was associated with improved HEI‐2015 (p = .001) at 1 year. Higher HEI‐2015 (p = .04) and married/living with someone (p = .05) were associated with higher odds of participating in strength training at 1 year.Conclusions: This year‐long lifestyle intervention for patients with breast cancer undergoing chemotherapy resulted in increases in PA and suggestive improvements in diet quality. Behavior change was associated with baseline fatigue, diet quality, education, and married/living with someone. Addressing these factors in interventions may improve uptake of lifestyle behaviors in trials during and after chemotherapy.


  • Impact of the Breast Cancer Index for Extended Endocrine Decision-Making: First Results of the Prospective BCI Registry Study

    by Tara B. Sanft, Jenna Wong, Brandon O’nEal, Natalia Siuliukina, Rachel C. Jankowitz, Mark D. Pegram, Jenny R. Fox, Yi Zhang, Kai Treuner, Joyce A. O’sHaughnessy

    Background: The Breast Cancer Index (BCI) test assay provides an individualized risk of late distant recurrence (5–10 years) and predicts the likelihood of benefitting from extended endocrine therapy (EET) in hormone receptor–positive early-stage breast cancer. This analysis aimed to assess the impact of BCI on EET decision-making in current clinical practice. Methods: The BCI Registry study evaluates long-term outcomes, decision impact, and medication adherence in patients receiving BCI testing as part of routine clinical care. Physicians and patients completed pre-BCI and post-BCI test questionnaires to assess a range of questions, including physician decision-making and confidence regarding EET; patient preferences and concerns about the cost, side effects, drug safety, and benefit of EET; and patient satisfaction regarding treatment recommendations. Pre-BCI and post-BCI test responses were compared using McNemar’s test and Wilcoxon signed rank test. Results: Pre-BCI and post-BCI questionnaires were completed for 843 physicians and 823 patients. The mean age at enrollment was 65 years, and 88.4% of patients were postmenopausal. Of the tumors, 74.7% were T1, 53.4% were grade 2, 76.0% were N0, and 13.8% were HER2-positive. Following BCI testing, physicians changed EET recommendations in 40.1% of patients (P<.0001), and 45.1% of patients changed their preferences for EET (P<.0001). In addition, 38.8% of physicians felt more confident in their recommendation (P<.0001), and 41.4% of patients felt more comfortable with their EET decision (P<.0001). Compared with baseline, significantly more patients were less concerned about the cost (20.9%; P<.0001), drug safety (25.4%; P=.0014), and benefit of EET (29.3%; P=.0002). Conclusions: This analysis in a large patient cohort of the BCI Registry confirms and extends previous findings on the significant decision-making impact of BCI on EET. Incorporating BCI into clinical practice resulted in changes in physician recommendations, increased physician confidence, improved patient satisfaction, and reduced patient concerns regarding the cost, drug safety, and benefit of EET.


  • Top Cited Papers
    Open Access

    Randomized Trial of Exercise and Nutrition on Chemotherapy Completion and Pathologic Complete Response in Women With Breast Cancer: The Lifestyle, Exercise, and Nutrition Early After Diagnosis Study

    by Tara Sanft, Maura Harrigan, Courtney McGowan, Brenda Cartmel, Michelle Zupa, Fang-Yong Li, Leah M. Ferrucci, Leah Puklin, Anlan Cao, Thai Hien Nguyen, et al.

    PURPOSE: Successful completion of chemotherapy is critical to improve breast cancer outcomes. Relative dose intensity (RDI), defined as the ratio of chemotherapy delivered to prescribed, is a measure of chemotherapy completion and is associated with cancer mortality. The effect of exercise and eating a healthy diet on RDI is unknown. We conducted a randomized trial of an exercise and nutrition intervention on RDI and pathologic complete response (pCR) in women diagnosed with breast cancer initiating chemotherapy. METHODS: One hundred seventy-three women with stage I-III breast cancer were randomly assigned to usual care (UC; n = 86) or a home-based exercise and nutrition intervention with counseling sessions delivered by oncology-certified registered dietitians (n = 87). Chemotherapy dose adjustments and delays and pCR were abstracted from electronic medical records. T-tests and chi-square tests were used to examine the effect of the intervention versus UC on RDI and pCR. RESULTS: Participants randomly assigned to intervention had greater improvements in exercise and diet quality compared with UC ( P < .05). RDI was 92.9% ± 12.1% and 93.6% ± 11.1% for intervention and UC, respectively ( P = .69); the proportion of patients in the intervention versus UC who achieved ≥85% RDI was 81% and 85%, respectively ( P = .44). The proportion of patients who had at least one dose reduction and/or delay was 38% intervention and 36% UC ( P = .80). Among 72 women who received neoadjuvant chemotherapy, women randomly assigned to intervention were more likely to have a pCR than those randomly assigned to UC (53% v 28%; P = .037). CONCLUSION: Although a diet and exercise intervention did not affect RDI, the intervention was associated with a higher pCR in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative and triple-negative breast cancer undergoing neoadjuvant chemotherapy.


  • Open Access

    Randomized Trial Evaluating a Self-Guided Lifestyle Intervention Delivered via Evidence-Based Materials versus a Waitlist Group on Changes in Body Weight, Diet Quality, Physical Activity, and Quality of Life among Breast Cancer Survivors

    by Leah S. Puklin, Maura Harrigan, Brenda Cartmel, Tara Sanft, Linda Gottlieb, Bin Zhou, Leah M. Ferrucci, Fang-Yong Li, Donna Spiegelman, Mona Sharifi, et al.

    Background: Lifestyle interventions for breast cancer survivors have proved effective at stimulating positive behavior change and promoting healthy weight loss, although integrating these programs into clinical practice is challenging. We evaluated the effect of a 6-month, unsupervised, self-guided, lifestyle intervention using printed materials and online videos vs. waitlist group on body weight for breast cancer survivors. Methods: The Lifestyle, Exercise and Nutrition (LEAN) Self-Guided trial randomized breast cancer survivors with a body mass index ≥25 kg/m2 to a 6-month lifestyle intervention (N = 102) or waitlist group (N = 103). Effects of the intervention on self-reported body weight, physical activity (PA), diet quality (via Health Eating Index—2010 (HEI-2010)), and quality of life were assessed using mixed model repeated measures analysis. Results: At 6 months, the intervention arm had significantly greater weight loss compared with the waitlist group (mean difference = −1.3 kg, 95% confidence interval [CI] = −2.5, −0.13). We observed suggestive improvements in PA (mean difference = 18.7 min/week, 95% CI = −24.2, 61.6), diet quality (mean difference in HEI = 3.2 points, 95% CI = −0.20, 6.5), and fatigue (mean difference in Functional Assessment of Chronic Illness Therapy—Fatigue scale = 1.4 points, 95% CI = −1.1, 3.9). Conclusions: The LEAN Self-Guided intervention led to favorable weight changes over 6 months. Low-resource-intensive programs have the potential to be delivered in diverse healthcare settings and may support breast cancer survivors in achieving a healthy body weight.